Details of the Drug

General Information of Drug (ID: DM6WJO9)

Drug Name
Etodolac
Synonyms
etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolacum; Etodolaco; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1]
Pain MG30-MG3Z Approved [2]
Plasma cell myeloma 2A83.1 Approved [1]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 287.35
Logarithm of the Partition Coefficient (xlogp) 2.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
90% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The apparent oral clearance of drug is 49.1 mL/h/kg []
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.3 - 10.3 hours [5]
Metabolism
The drug is metabolized via the liver []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 69.6 micromolar/kg/day [6]
Vd
The volume of distribution (Vd) of drug is 0.39 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 0.01 mg/mL [3]
Chemical Identifiers
Formula
C17H21NO3
IUPAC Name
2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid
Canonical SMILES
CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O
InChI
InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)
InChIKey
NNYBQONXHNTVIJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3308
ChEBI ID
CHEBI:4909
CAS Number
41340-25-4
DrugBank ID
DB00749
TTD ID
D0N1WU
VARIDT ID
DR00648
INTEDE ID
DR0666
ACDINA ID
D00257
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [8]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [10]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [11]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Gene/Protein Processing [12]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [13]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [10]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Gene/Protein Processing [11]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [11]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [11]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Gene/Protein Processing [11]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.10E-01 -5.91E-02 -3.60E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Etodolac
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Aspirin. Pain [MG30-MG3Z] [14]
Coadministration of a Drug Treating the Disease Different from Etodolac (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [15]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Etodolac and Repaglinide. Acute diabete complication [5A2Y] [16]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Etodolac and Glibenclamide. Acute diabete complication [5A2Y] [16]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Etodolac and Tolazamide. Acute diabete complication [5A2Y] [16]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Etodolac and Glipizide. Acute diabete complication [5A2Y] [16]
Inotersen DMJ93CT Major Increased risk of bleeding by the combination of Etodolac and Inotersen. Amyloidosis [5D00] [17]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [18]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Budesonide. Asthma [CA23] [19]
Ofloxacin DM0VQN3 Moderate Additive CNS depression effects by the combination of Etodolac and Ofloxacin. Bacterial infection [1A00-1C4Z] [20]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Kanamycin. Bacterial infection [1A00-1C4Z] [21]
Sparfloxacin DMB4HCT Moderate Additive CNS depression effects by the combination of Etodolac and Sparfloxacin. Bacterial infection [1A00-1C4Z] [20]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Streptomycin. Bacterial infection [1A00-1C4Z] [21]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Etodolac and Gemifloxacin. Bacterial infection [1A00-1C4Z] [20]
Norfloxacin DMIZ6W2 Moderate Additive CNS depression effects by the combination of Etodolac and Norfloxacin. Bacterial infection [1A00-1C4Z] [20]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Etodolac and ABT-492. Bacterial infection [1A00-1C4Z] [20]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Gentamicin. Bacterial infection [1A00-1C4Z] [21]
Levofloxacin DMS60RB Moderate Additive CNS depression effects by the combination of Etodolac and Levofloxacin. Bacterial infection [1A00-1C4Z] [20]
Lomefloxacin DMVRH9C Moderate Additive CNS depression effects by the combination of Etodolac and Lomefloxacin. Bacterial infection [1A00-1C4Z] [20]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Etidronic acid. Bone paget disease [FB85] [22]
Risedronate DM5FLTY Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Risedronate. Bone paget disease [FB85] [22]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Etodolac and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [23]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of bleeding by the combination of Etodolac and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [24]
Iodipamide DMXIQYS Major Increased risk of nephrotoxicity by the combination of Etodolac and Iodipamide. Cholelithiasis [DC11] [25]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Etodolac and Regorafenib. Colorectal cancer [2B91] [17]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Etodolac and Drospirenone. Contraceptive management [QA21] [26]
Methoxyflurane DML0RAE Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Methoxyflurane. Corneal disease [9A76-9A78] [17]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Etodolac and Ardeparin. Coronary thrombosis [BA43] [27]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Etodolac and Danaparoid. Deep vein thrombosis [BD71] [27]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Etodolac and Rivaroxaban. Deep vein thrombosis [BD71] [28]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Etodolac and Sertraline. Depression [6A70-6A7Z] [29]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Etodolac and Vilazodone. Depression [6A70-6A7Z] [29]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Etodolac and Vortioxetine. Depression [6A70-6A7Z] [29]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Etodolac and Milnacipran. Depression [6A70-6A7Z] [29]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Etodolac and Escitalopram. Depression [6A70-6A7Z] [29]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Etodolac and Desvenlafaxine. Depression [6A70-6A7Z] [29]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Etodolac and Clomipramine. Depression [6A70-6A7Z] [29]
PMID28870136-Compound-49 DMTUC9E Moderate Increased risk of bleeding by the combination of Etodolac and PMID28870136-Compound-49. Discovery agent [N.A.] [30]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Cannabidiol. Epileptic encephalopathy [8A62] [17]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Etodolac when combined with Ethacrynic acid. Essential hypertension [BA00] [31]
Tazemetostat DMWP1BH Moderate Increased risk of bleeding by the combination of Etodolac and Tazemetostat. Follicular lymphoma [2A80] [24]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Etodolac and Avapritinib. Gastrointestinal stromal tumour [2B5B] [17]
Sulfinpyrazone DMEV954 Moderate Increased risk of bleeding by the combination of Etodolac and Sulfinpyrazone. Gout [FA25] [24]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Etodolac when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [31]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Etodolac when combined with Bumetanide. Heart failure [BD10-BD1Z] [31]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Etodolac when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [31]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Etodolac and Mipomersen. Hyper-lipoproteinaemia [5C80] [33]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Etodolac and Teriflunomide. Hyper-lipoproteinaemia [5C80] [34]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Etodolac and BMS-201038. Hyper-lipoproteinaemia [5C80] [35]
Indapamide DMGN1PW Moderate Antagonize the effect of Etodolac when combined with Indapamide. Hypertension [BA00-BA04] [31]
Trichlormethiazide DMHAQCO Moderate Antagonize the effect of Etodolac when combined with Trichlormethiazide. Hypertension [BA00-BA04] [31]
Dipyridamole DMXY30O Moderate Increased risk of bleeding by the combination of Etodolac and Dipyridamole. Hypertension [BA00-BA04] [24]
Potassium chloride DMMTAJC Moderate Increased risk of hyperkalemia by the combination of Etodolac and Potassium chloride. Hypo-kalaemia [5C77] [36]
Balsalazide DM7I1T9 Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Balsalazide. Indeterminate colitis [DD72] [37]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Etodolac and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [38]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Idelalisib. Mature B-cell leukaemia [2A82] [39]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Etodolac and Acalabrutinib. Mature B-cell lymphoma [2A85] [40]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Etodolac and Ponatinib. Mature B-cell lymphoma [2A85] [41]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Etodolac and Exjade. Mineral absorption/transport disorder [5C64] [42]
Panobinostat DM58WKG Major Increased risk of bleeding by the combination of Etodolac and Panobinostat. Multiple myeloma [2A83] [15]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Deflazacort. Muscular dystrophy [8C70] [19]
Ruxolitinib DM7Q98D Moderate Increased risk of bleeding by the combination of Etodolac and Ruxolitinib. Myeloproliferative neoplasm [2A20] [24]
Dasatinib DMJV2EK Major Increased risk of bleeding by the combination of Etodolac and Dasatinib. Myeloproliferative neoplasm [2A20] [43]
Omacetaxine mepesuccinate DMPU2WX Major Increased risk of bleeding by the combination of Etodolac and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [44]
Prasugrel DM7MT6E Major Increased risk of bleeding by the combination of Etodolac and Prasugrel. Myocardial infarction [BA41-BA43] [17]
Vorapaxar DMA16BR Major Increased risk of bleeding by the combination of Etodolac and Vorapaxar. Myocardial infarction [BA41-BA43] [45]
Tirofiban DMQG17S Moderate Increased risk of bleeding by the combination of Etodolac and Tirofiban. Myocardial infarction [BA41-BA43] [46]
Dexfenfluramine DMJ7YDS Moderate Increased risk of bleeding by the combination of Etodolac and Dexfenfluramine. Obesity [5B80-5B81] [29]
Polythiazide DMCH80F Moderate Antagonize the effect of Etodolac when combined with Polythiazide. Oedema [MG29] [31]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Etodolac and MK-4827. Ovarian cancer [2C73] [17]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Etodolac and Epoprostenol. Pulmonary hypertension [BB01] [47]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Etodolac and Iloprost. Pulmonary hypertension [BB01] [47]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Etodolac and Everolimus. Renal cell carcinoma [2C90] [48]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Etodolac and Temsirolimus. Renal cell carcinoma [2C90] [48]
Gatifloxacin DMSL679 Moderate Additive CNS depression effects by the combination of Etodolac and Gatifloxacin. Respiratory infection [CA07-CA4Z] [20]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Sulfasalazine. Rheumatoid arthritis [FA20] [37]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Dexamethasone. Rheumatoid arthritis [FA20] [19]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Etodolac and Leflunomide. Rheumatoid arthritis [FA20] [34]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [19]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Etodolac and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [17]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [19]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Etodolac and Pitolisant. Somnolence [MG42] [17]
Caplacizumab DMPUKA7 Moderate Increased risk of bleeding by the combination of Etodolac and Caplacizumab. Thrombocytopenia [3B64] [24]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Etodolac and Apixaban. Thrombosis [DB61-GB90] [17]
Cangrelor DM8JRH0 Moderate Increased risk of bleeding by the combination of Etodolac and Cangrelor. Thrombosis [DB61-GB90] [24]
Brilinta DMBR01X Moderate Increased risk of bleeding by the combination of Etodolac and Brilinta. Thrombosis [DB61-GB90] [17]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Etodolac and Cabozantinib. Thyroid cancer [2D10] [49]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Etodolac and Sirolimus. Transplant rejection [NE84] [48]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Etodolac and Tacrolimus. Transplant rejection [NE84] [48]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Olsalazine. Ulcerative colitis [DD71] [37]
Cinoxacin DM4EWNS Moderate Additive CNS depression effects by the combination of Etodolac and Cinoxacin. Urinary tract infection [GC08] [20]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Etodolac and Plazomicin. Urinary tract infection [GC08] [21]
Nalidixic acid DMRM0JV Moderate Additive CNS depression effects by the combination of Etodolac and Nalidixic acid. Urinary tract infection [GC08] [20]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Etodolac and Betrixaban. Venous thromboembolism [BD72] [50]
⏷ Show the Full List of 94 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
D&C red no. 33 E00261 19116 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Calcium hydrogenphosphate E00294 24441 Diluent
Carmellose sodium E00625 Not Available Disintegrant
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Disodium hydrogenorthophosphate E00283 24203 Buffering agent; Complexing agent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
⏷ Show the Full List of 36 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Etodolac 200 mg capsule 200 mg Oral Capsule Oral
Etodolac 300 mg capsule 300 mg Oral Capsule Oral
Etodolac 600 mg tablet 600 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 500 mg tablet 500 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 400 mg tablet 400 mg 24 HR Extended Release Oral Tablet Oral
Etodolac 400 mg tablet 400 mg Oral Tablet Oral
Etodolac 500 mg tablet 500 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Etodolac FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7185).
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
8 Stereoselective glucuronidation and hydroxylation of etodolac by UGT1A9 and CYP2C9 in man. Xenobiotica. 2004 May;34(5):449-61.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
11 Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res. 2006 Feb;30(2):123-35. doi: 10.1016/j.leukres.2005.06.009. Epub 2005 Jul 25.
12 Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells. Eur J Haematol. 2005 Sep;75(3):212-20. doi: 10.1111/j.1600-0609.2005.00498.x.
13 Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol. 2005 Sep 1;70(5):658-67.
14 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
15 Cerner Multum, Inc. "Australian Product Information.".
16 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
19 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
20 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
21 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
22 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
23 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
24 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
25 Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
26 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
27 Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
28 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
29 Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
30 Canadian Pharmacists Association.
31 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
32 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
33 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
34 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
35 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
36 Product Information. Potassium Chloride ER (potassium chloride). Zydus Pharmaceuticals (USA) Inc, Princeton, NJ.
37 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
38 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
39 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
40 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
41 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
42 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
44 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
45 Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
46 Product Information. Integrilin (eptifibatide). Schering Laboratories, Kenilworth, NJ.
47 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
48 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
49 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
50 Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.